Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
ENTA > SEC Filings for ENTA > Form 8-K on 5-Mar-2014All Recent SEC Filings

Show all filings for ENANTA PHARMACEUTICALS INC

Form 8-K for ENANTA PHARMACEUTICALS INC


5-Mar-2014

Other Events, Financial Statements and Exhibits


Item 8.01 Other Events.

On March 3, 2014, Enanta Pharmaceuticals, Inc. issued a press release announcing detailed results from the PEARL-III study conducted by AbbVie for the treatment of the hepatitis C virus, or HCV, with a regimen containing Enanta's lead protease inhibitor ABT-450, which were presented as part of the 21st Conference on Retroviruses and Opportunistic Infections (CROI) in Boston. A copy of the press release is being filed as Exhibit 99.1 to this report.

On March 4, 2014, Enanta Pharmaceuticals, Inc. issued a press release announcing new in vitro data on ABT-493, an NS3/4 protease inhibitor identified within the Enanta-AbbVie collaboration, which was presented at the 21st Conference on Retroviruses and Opportunistic Infections (CROI) in Boston. A copy of the press release is being filed as Exhibit 99.2 to this report.

Both press releases contain forward-looking statements which involve certain risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Please refer to the cautionary note in each of the press releases regarding these forward-looking statements.



Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit
  No.                                     Description

99.1         Press release titled "PEARL-III Study Results in Patients with Chronic
             Hepatitis C Presented at the 21st Conference on Retroviruses and
             Opportunistic Infections (CROI)" issued by Enanta Pharmaceuticals,
             Inc. on March 3, 2014.

99.2         Press release titled "Enanta Pharmaceuticals Announces New Data
             Presented on Protease Inhibitor ABT-493 at the 21st Conference on
             Retroviruses and Opportunistic Infections (CROI)" issued by Enanta
             Pharmaceuticals, Inc. on March 4, 2014.


  Add ENTA to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for ENTA - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.